Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 31 results for "glenn saldanha"

Out-licensing yes, but with a more ‘mature’ approach, says...

Glenn Saldanha does not believe that Glenmark has fallen silent on the licensing front. The next 12 to 18 months will see the company venture into out-licensing pacts with global partners to develop prospective drugs from the Glenmark stable, says Saldanha, ... Business Line, 2 months ago

1 images for "glenn saldanha"

Business Standard India, 6 months ago

Expect better performance from core US biz in Q3: Glenmark

Glenn Saldanha says Zetia Generic - a drug to keep a check on cholestrol levels - will be launched on December 12. The launch could see USD 200-250 million in revenues. The company is going to use the money from here to bring down company's debt.
 Money Control1 month ago
Daijiworldcom

Alban Denis Mudartha (DSouza) (78), Pilar, Shirva

From Arun Denis Mudartha Alban Denis Mudartha (DSouza) (78), from Mithabeetu village, Pilar, Shirva S/o late Salvador Mudartha D'Souza and late Serphine Mudartha DSouza, H/o Dorothy D'Souza ( Cutinho) of Pernal village Shirva, F/o Arun Denis ...
 Daijiworldcom1 week ago

Glenmark leads growth in diabetes drugs market

Tenelegliptin, an anti-diabetic drug launched a year ago by Glenmark, has emerged as the preferred line of treatment for Type 2 diabetes because of its price and several pharmaceutical companies are now scrambling for a share of this market. The ...
 Smart Investor2 weeks ago Teneligliptin topples other diabetes drugs in growth  Smart Investor2 weeks ago
Livemint.com

Glenmark: steering financial deleverage through new products

Glenmark sales, aided by strong growth in the US, increased by a healthy 16.5% but net profit grew just 3.5% and missed analysts estimates The Glenmark Pharmaceuticals Ltd stock has been falling steadily in the past few days. The company's September ...
 Livemint.com1 month ago Glenmark's Q2 profit grows at 3.5% despite 16% rise in revenue  Livemint.com1 month ago Glenmark Pharma posts 3.5% rise in net profit in Q2  Economic Times1 month ago Glenmark rises armed with research after five year hiatus  Economic Times1 month ago

Glenmark aims for substantial debt reduction in FY17

Email this Print Drug maker Glenmark has said that improved sales in the US market will help it substantially reduce its Rs 4,600 crore debt in FY 2017. Glenmark, which reported 3.5% growth in net profit in second quarter FY 2017 on a ...
 Smart Investor1 month ago
Hindu Business Line

Stocks in focus: Inox Leisure, Glenmark Pharma, Tech Mahindra

Shares of multiplex operator Inox Leisure today slumped nearly 9 per cent after the company reported a decline of 92.56 per cent in its consolidated net profit for the second quarter ended September. The stock tanked 8.74 per cent to Rs 240 on the ...
 Hindu Business Line1 month ago Glenmark Pharma shares gain over 4% post Q2 results  DNA India1 month ago

Glenmark Pharma gains after decent Q2 results

Glenmark Pharmaceuticals rose 2.09% to Rs 925.35 at 10:35 IST on BSE after net profit rose 3.46% to Rs 223.59 crore on 15.67% rise in net sales to Rs 2173.18 crore in Q2 September 2016 over Q2 September 2015. The result was announced after market ...
 Capital Market1 month ago GLENMARK PHARMACEUTICALS : Pharma gains after decent Q2 results  4 Traders1 month ago

Glenmark Pharma Q2 up 3% to Rs 223 cr

Glenmark Pharma today reported 3.46 per cent rise in consolidated net profit to Rs 223.58 crore for the second quarter ended September 30, 2016-17. It had reported net profit of Rs 216.10 crore for the July-September quarter of the 2015-16 fiscal, ...
 Moneycontrol.com1 month ago Glenmark Pharma net marginally higher by 3.5% in Q2 to Rs.224 cr  PharmaBiz1 month ago GLENMARK PHARMACEUTICALS : Pharma net marginally higher by 3.5% in Q2 to Rs.224 cr  4 Traders1 month ago

Glenmark Pharmaceuticals cons revenue up by 16% in Q2 FY17

Consolidated Net Profit for Q2 FY 16-17 was Rs. 223 crore as compared to Rs. 216 crore in the previous corresponding quarter; an increase of 3.5%. Consolidated EBITDA was at Rs. 448 crore in Q2 FY16-17 as compared to Rs. 403 crore in the previous ...
 India Infoline1 month ago GLENMARK PHARMACEUTICALS : cons revenue up by 16% in Q2 FY17  4 Traders1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less